Press release 05.05.2026
1 in 5 people will receive radiotherapy at some point. For decades, radiotherapy has optimised treatment plans to give the best possible dose to cancer patients. But ask any clinician if they know which dose their patient actually received, and the answer is surprisingly uncertain.
Thomas Ravkilde and Per Poulsen saw this gap firsthand. Both researchers with long clinical experience, they studied why radiotherapy measured everything except the one thing that mattered: what dose was actually delivered. Their findings ultimately led to the creation of Ardos.
Ardos is a Danish medtech company developing DoseTracker, a software-only system that calculates and verifies the radiation dose delivered to cancer patients in real time during radiotherapy. Today, clinicians are forced to rely on static treatment plans and indirect motion-management tools, leaving uncertainty about whether the patient is treated as intended.
With a new investment from Delphinus Venture Capital, the company is now set to bring real-time dose verification into clinical practice.
From a mentor–student relationship to co-founders
Thomas started as Per’s PhD student working on tumor tracking. When tumors move during treatment, the dose distribution changes. Tumor tracking tries to keep the radiation focused on the moving tumor by adjusting the treatment on the fly, similar to a missile tracking system. But clinicians still lack real-time confirmation of where the dose actually goes—including whether nearby healthy organs suddenly receive more radiation than intended.
“We had no idea what it meant in terms of dose, since no one was tracking it—so we developed an algorithm. The criteria were conceptually simple: it had to be accurate, flexible, and fast,” Thomas Ravkilde explains.
Thomas moved into the clinic after his PhD and kept working on the problem. Per kept pushing from the research side. Over years, they refined the approach.
When they published their initial findings, clinicians’ response was immediate: they had been waiting for this solution.
In 2023, Lene Ploug Bülow joined as working chairperson and has since played a pivotal role in accelerating both the commercial expansion strategy and the full R&D roadmap—driving the company rapidly from concept to market readiness. Today, she is Chair of the Board, co-owner, and a central member of Ardos’ founding team.
The vision
Thomas articulates the longer view: “The dream is to bring radiotherapy into the real-time era. Thirty years ago you drew upon images by hand, then you got image-guidance, and moved into the digital space.”
“Many research projects never make it to the clinic, and that is what drives me. At the core of research is the idea of making new findings applicable in the real world,” Per states.
Lene adds: “in my career I’ve seen many great medtech ideas—but it is rare to find one as impactful as Ardos’ combination of clinical need, scientific depth, and commercial potential. It has the potential to improve both clinical workflows and patient outcomes.”
Delphinus Venture Capital is investing in Ardos to support the company’s hiring, regulatory progress, and go-to-market strategy.
About Ardos
Ardos is a Danish medtech company developing DoseTracker, a software-only, vendor-agnostic platform for real-time dose verification and adaptation in radiotherapy. DoseTracker calculates the dose actually delivered to the patient during treatment, including the effects of patient motion and anatomical changes. By giving clinicians real-time insight into delivered dose, Ardos aims to improve treatment precision, support adaptive workflows, and make advanced radiotherapy safer and more efficient.
About Delphinus Venture Capital
Delphinus Venture Capital is a Danish venture fund established in 2025, managing EUR 80 million. Backed by Aarhus University Research Foundation, HEARTLAND, Norlys, and Salling Group, the fund invests in research-driven innovation and deep tech companies with global impact.
For further information:
Magnus Theil Olsen
Investment Associate, Delphinus Venture Capital
+45 20 68 92 95